WO1998044948A3 - Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties - Google Patents
Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties Download PDFInfo
- Publication number
- WO1998044948A3 WO1998044948A3 PCT/CA1998/000325 CA9800325W WO9844948A3 WO 1998044948 A3 WO1998044948 A3 WO 1998044948A3 CA 9800325 W CA9800325 W CA 9800325W WO 9844948 A3 WO9844948 A3 WO 9844948A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immune globulin
- active agent
- surface active
- ionic surface
- formulation containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98914750A EP0973549A2 (en) | 1997-04-07 | 1998-04-07 | Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties |
AU69149/98A AU6914998A (en) | 1997-04-07 | 1998-04-07 | Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4192197P | 1997-04-07 | 1997-04-07 | |
US60/041,921 | 1997-04-07 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998044948A2 WO1998044948A2 (en) | 1998-10-15 |
WO1998044948A3 true WO1998044948A3 (en) | 1999-02-11 |
WO1998044948B1 WO1998044948B1 (en) | 1999-04-01 |
Family
ID=21919058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1998/000325 WO1998044948A2 (en) | 1997-04-07 | 1998-04-07 | Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0973549A2 (en) |
AU (1) | AU6914998A (en) |
WO (1) | WO1998044948A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7914801B1 (en) * | 2002-03-21 | 2011-03-29 | The United States Of America As Represented By The Secretary Of Agriculture | Metabolizable oil emulsion adjuvants and vaccines for enhancing immuno-properties of antibodies and their subpopulations |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
FR2853551B1 (en) * | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | STABILIZING FORMULATION FOR IMMUNOGLOBULIN G COMPOSITIONS IN LIQUID FORM AND LYOPHILIZED FORM |
CN101679507A (en) | 2007-03-29 | 2010-03-24 | 艾博特公司 | crystalline anti-human il-12 antibodies |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
FR2961107B1 (en) * | 2010-06-15 | 2012-07-27 | Lab Francais Du Fractionnement | HUMAN IMMUNOGLOBULIN COMPOSITION STABILIZED |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0073371A2 (en) * | 1981-08-24 | 1983-03-09 | Miles Laboratories, Inc. | Intravenously injectable immune serum globulin and method of preparing same |
EP0278422A2 (en) * | 1987-02-06 | 1988-08-17 | Green Cross Corporation | y-Globulin injectable solutions |
EP0318081A1 (en) * | 1987-11-27 | 1989-05-31 | Akzo N.V. | Stabilization of antibodies |
WO1995001155A1 (en) * | 1993-07-01 | 1995-01-12 | Unilever N.V. | Oral compositions |
CA2151409A1 (en) * | 1995-05-05 | 1996-11-06 | Juan Carlos Rodriguez | Formulation for stabilizing human immunoglobulins |
EP0764447A2 (en) * | 1995-09-22 | 1997-03-26 | Bayer Corporation | Preparation of virally inactivated intravenously injectable immune serum globulin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1064396A (en) | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
JPH0778025B2 (en) | 1990-03-20 | 1995-08-23 | 日本赤十字社 | Method for producing immunoglobulin G |
FR2708467B1 (en) | 1993-07-30 | 1995-10-20 | Pasteur Merieux Serums Vacc | Stabilized immunoglobulin preparations and process for their preparation. |
-
1998
- 1998-04-07 EP EP98914750A patent/EP0973549A2/en not_active Withdrawn
- 1998-04-07 WO PCT/CA1998/000325 patent/WO1998044948A2/en not_active Application Discontinuation
- 1998-04-07 AU AU69149/98A patent/AU6914998A/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0073371A2 (en) * | 1981-08-24 | 1983-03-09 | Miles Laboratories, Inc. | Intravenously injectable immune serum globulin and method of preparing same |
EP0278422A2 (en) * | 1987-02-06 | 1988-08-17 | Green Cross Corporation | y-Globulin injectable solutions |
EP0318081A1 (en) * | 1987-11-27 | 1989-05-31 | Akzo N.V. | Stabilization of antibodies |
WO1995001155A1 (en) * | 1993-07-01 | 1995-01-12 | Unilever N.V. | Oral compositions |
CA2151409A1 (en) * | 1995-05-05 | 1996-11-06 | Juan Carlos Rodriguez | Formulation for stabilizing human immunoglobulins |
EP0764447A2 (en) * | 1995-09-22 | 1997-03-26 | Bayer Corporation | Preparation of virally inactivated intravenously injectable immune serum globulin |
Non-Patent Citations (2)
Title |
---|
KALEVI J.A. ET AL.: "Modulation of antibody kinetics by the cell membrane active agent tween 80 in vivo", ANTICANCER RESEARCH, vol. 16, no. 6b, 1996, pages 3542 - 3550, XP002085447 * |
See also references of EP0973549A2 * |
Also Published As
Publication number | Publication date |
---|---|
EP0973549A2 (en) | 2000-01-26 |
AU6914998A (en) | 1998-10-30 |
WO1998044948A2 (en) | 1998-10-15 |
WO1998044948B1 (en) | 1999-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2569949T3 (en) | Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine | |
KR100861443B1 (en) | Controlled release delivery system for nasal applications | |
GB0015617D0 (en) | Improved preparations for dermal delivery of active substances | |
AU681452B2 (en) | Pernasal composition and pernasal preparation containing thesame | |
GB2316004B (en) | Novel formulations for transdermal delivery of pergolide | |
CA2276170A1 (en) | Sustained analgesia achieved with buprenorphine | |
MY118371A (en) | Tetrahydrolipstatin containing compositions | |
CY2503B1 (en) | Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate. | |
HUP0100606A2 (en) | Long acting injectable formulations containing hydrogenated castor oil | |
CA2046014A1 (en) | Reduction or prevention of skin irritation by drugs | |
WO1998042322A3 (en) | Antitussive compositions | |
EP1201246A3 (en) | Use of Thrombopoietin as a medicament for the therapy and prevention of thrombocytopenia | |
RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
WO1998044948A3 (en) | Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties | |
CA2433833A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
WO2000010533A3 (en) | Compositions and methods for treating intracellular infections | |
CA2118512A1 (en) | Agents for treating substance abuse disorders | |
JP2002530353A5 (en) | ||
CA2406179A1 (en) | Use of defibrotide and at least one haematopoietic factor to mobilize haematopoietic progenitors | |
US5380710A (en) | Pharmaceutical compositions containing ACTH (1-24) for the therapy of shock conditions and respiratory and cardiocirculatory insufficiences | |
WO2001041771A3 (en) | Transdermal system containing acetylsalicylic acid for treatment of migraine | |
US4885288A (en) | Pharmaceutical compositions containing lysine acetylsalicylate | |
CA2251353A1 (en) | Transdermal delivery device for azapirone compounds | |
MD1568G2 (en) | Method of treatment of the burn disease in the burn shock period | |
Harder | Interaction of quinolones with other pharmaceuticals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998914750 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09402446 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998914750 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998542188 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998914750 Country of ref document: EP |